Both Type I and type II IFN signatures have been detected for SS patients and genetic ablation of interferon α receptor 1 (IFNAR1), IFN-γ, or its receptor IFNγR prevent the onset of disease in the spontaneous SS models: the non-obese diabetic (NOD) mouse and it’s derivative C57BL/6.NOD-Aec1Aec2 [20,21,22,23]. Here, IFNG is linked to synovial sarcoma.